SHENZHEN BIOEASY BIOTECHNOLOGY CO., LTD. Shenzhen Bioeasy Biotechnology Co., Ltd. Share Price
Equities
300942
CNE100004C78
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.06 CNY | +1.15% |
|
+9.46% | -39.61% |
| Sales 2022 | 687M 94.86M 7.57B | Sales 2023 | 254M 35.09M 2.8B | Capitalization | 4.69B 647M 51.66B |
|---|---|---|---|---|---|
| Net income 2022 | 83M 11.46M 915M | Net income 2023 | -185M -25.55M -2.04B | EV / Sales 2022 | 9.55 x |
| Net cash position 2022 | 310M 42.81M 3.42B | Net cash position 2023 | 236M 32.58M 2.6B | EV / Sales 2023 | 17.5 x |
| P/E ratio 2022 |
81.6
x | P/E ratio 2023 |
-25.4
x | Employees | 635 |
| Yield 2022 |
0.12% | Yield 2023 |
-
| Free-Float | 22.42% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.15% | ||
| 1 week | +9.46% | ||
| Current month | -19.50% | ||
| 1 month | -17.62% | ||
| 3 months | -31.59% | ||
| 6 months | -41.41% | ||
| Current year | -39.61% |
1 week
6.30
7.41
1 month
6.139.11
Current year
5.2511.90
1 year
5.2516.88
3 years
5.2543.60
5 years
5.2552.80
10 years
5.2552.80
| Managers | Title | Age | Since |
|---|---|---|---|
Zhao Li Xiao
CEO | Chief Executive Officer | 50 | 28/07/22 |
Kai Wan
DFI | Director of Finance/CFO | 42 | 26/12/21 |
Mei Xia Li
CHM | Chairman | 36 | 31/05/12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hui Fu
BRD | Director/Board Member | 40 | 29/02/08 |
Xi Li Wang
BRD | Director/Board Member | 39 | 30/06/10 |
Mei Xia Li
CHM | Chairman | 36 | 31/05/12 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 7.06 | +1.15% | 4,938,211 |
| 25/04/24 | 6.98 | +2.65% | 4,318,400 |
| 24/04/24 | 6.8 | +1.19% | 3,805,265 |
| 23/04/24 | 6.72 | +6.33% | 6,542,223 |
| 22/04/24 | 6.32 | -2.02% | 5,695,954 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
Shenzhen Bioeasy Biotechnology Co Ltd is a China-based company mainly engaged in the research, development, production, sales and provision of food safety testing products and related services. The Companyâs main products are food safety rapid testing reagents, rapid testing instruments, related testing services and in vitro diagnostic point-of-car testing (POCT) products, such as colloidal gold immunochromatographic test papers, enzyme-linked immunoassay (ELISA) kits, nucleic acids extraction kit, portable food rapid analysis system, infectious disease detection series and fluorescence immunoassay analyzer, etc. Its products are mainly used in dairy, meat, aquatic products, grains and oils, fruits and vegetables and other food fields that require rapid testing, as well as in the cultivation and breeding fields.
Calendar
16/05/2024
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -39.61% | 391M | |
| +1.19% | 12.8B | |
| -10.29% | 7.61B | |
| +3.54% | 5.41B | |
| -1.16% | 4.51B | |
| +5.74% | 4.49B | |
| +12.21% | 2.73B | |
| -14.33% | 2.02B | |
| -11.50% | 1.73B | |
| -5.02% | 1.64B |
- Stock Market
- Equities
- 300942 Stock
